UroGen Pharma price target raised to $31 from $10 at Oppenheimer
Oppenheimer analyst Leland Gershell raised the firm's price target on UroGen Pharma (URGN) to $31 from $10 and keeps an Outperform rating on the shares following yesterday's approval of Zusduri. The firm says key reveal on this morning's conference call was the $21,500 per-dose list price. Oppenheimer awaits clarity on the approval path for UGN-103, which is needed to extend franchise exclusivity beyond early 2031, but notes management does not expect the potential need for a randomized controlled trial in lieu of the recently-initiated single-arm study to materially alter its financial outlook. The analyst sees $1B in sales over time and would would take advantage of any near-term weakness to buy UroGen shares.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Despite Limited Near-Term Catalysts, Oppenheimer Reaffirms Salesforce (CRM) at Overweight
Salesforce Inc. (NYSE:CRM) is one of the 10 best tech stocks to buy according to billionaires right now. On June 9, an analyst at Oppenheimer reiterated his Outperform rating on the stock and maintained a $370 price target. In this latest note, the analyst pointed to a positive tone from the company management in their recent meeting, particularly around product demand, AI platform capabilities, and early-stage pipeline momentum. Within the AI platforms, he was specifically upbeat about traction in Agentforce and Data Cloud. Copyright: drserg / 123RF Stock Photo However, despite the constructive messaging, the analyst acknowledged that short-term catalysts appear limited. The recent announcement of a potential deal with Informatica Inc. (NYSE:INFA) is also weighing on sentiment for now. The company's historical track record in integration of acquired companies is not particularly strong, and thus the market is still cautious on the long-term synergies of this acquisition. That said, the Oppenheimer analyst maintains a longer-term positive view, citing Salesforce's strong position in the evolving AI landscape. The firm believes Salesforce is well placed to serve as a primary data layer and system-of-records provider in enterprise AI adoption. In the first week of June, an analyst from Cantor Fitzgerald also initiated coverage on Salesforce with an Overweight rating and a price target of $325. He cited the company as one of the highest-quality businesses within their coverage. Salesforce Inc. (NYSE:CRM) is a cloud-based software company specializing in customer relationship management (CRM) solutions. The company offers a comprehensive suite of cloud-based applications for sales, service, marketing, and analytics, enabling businesses to connect with their customers more meaningfully. Its platform is designed to help organizations streamline their operations, enhance customer engagement, and drive growth through data-driven insights. While we acknowledge the potential of CRM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Ascendis Pharma price target raised to $224 from $215 at Oppenheimer
Oppenheimer raised the firm's price target on Ascendis Pharma (ASND) to $224 from $215 and keeps an Outperform rating on the shares. The firm's commissioned survey of 20 U.S. hypoparathyroid-treating endocrinologists indicates robust early demand for Yorvipath, with about 20%-30% of its respondents' hypoPT patients expected to be on drug one year hence. While this lines up with the renal impairment rate across the hypoPT population, 90% of its surveyed physicians would reach for Yorvi to preserve kidney function ahead of such impairment. Access/reimbursement was pointed to as the largest adoption hurdle by most of the docs, but this may be more anticipation than reality. Oppenheimer believes Yorvi's strong first full U.S. quarter was just the beginning of a launch that will outpace expectations. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ASND: Disclaimer & DisclosureReport an Issue Ascendis Pharma Grants Employee Warrants to Boost Retention Ascendis Pharma's TransCon CNP and hGH Combination Therapy: Best-in-Class Efficacy and Market Potential Justify Buy Rating Ascendis Pharma's Promising Growth Potential Backed by Strong Trial Results and Product Launches Ascendis Pharma Reveals Promising Interim Results from COACH Trial for Achondroplasia Ascendis Pharma Reports Promising Interim Results from COACH Trial
Business Insider
2 days ago
- Business Insider
AMD Stock Slips 2% Despite Analyst Updates
Advanced Micro Devices (AMD) stock was down on Friday after analysts updated their coverage of the semiconductor company's shares. These updates followed its Advancing AI event yesterday, which included new chip announcements. Confident Investing Starts Here: This spurred several top analysts to update their coverage of AMD stock: Oppenheimer analyst Rick Schafer reiterated a Hold rating. Wells Fargo analyst Aaron Rakers maintained a Buy rating and $120 price target. Evercore ISI analyst Mark Lipacis kept a Buy rating and increased his price target to $144 from $120. Bank of America Securities analyst Vivek Arya reiterated a Buy rating and $130 price target. Robert W. Baird analyst Tristan Gerra maintained a Buy rating and $140 price target. J.P. Morgan analyst Harlan Sur kept a Hold rating and $120 price target. Stifel Nicolaus analyst Ruben Roy reiterated a Buy rating and $132 price target. Roth MKM analyst Sujeeva De Silva maintained a Buy rating and increased his price target to $150 from $125. Benchmark Co. analyst Cody Acree kept a Buy rating and $170 price target. Morgan Stanley analyst Joseph Moore reiterated a Hold rating and $121 price target. Barclays analyst Thomas O'Malley maintained a Buy rating and $130 price target. Citi analyst Christopher Danely kept a Hold rating and increased his price target to $120 from $100. AMD Stock Movement Today AMD stock was down 1.95% on Friday morning, extending a 3.81% year-to-date decrease. The shares have also decreased 25.77% over the past 12 months. Is AMD Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for AMD is Moderate Buy, based on 22 Buy and 11 Hold ratings over the past three months. With that comes an average AMD stock price target of $129.41, representing a potential 11.52% upside for the shares.
